STIFEL 2026 HEALTHCARE CONFERENCE - DEFINIUM THERAPEUTICS INC

Financial Performance:

• No specific financial metrics (revenue, earnings, cash flow, debt) were disclosed in the transcript; the call focused exclusively on clinical and regulatory updates.
• The company currently employs 194 people (as of Monday) with a rapid hiring rate of approximately 10 employees per week.

Guidance and Future Outlook:

• DT120 NDA Filing: Plans to submit a New Drug Application (NDA) to the FDA in the first half of next year for both Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).
• Filing Strategy: The base case remains a simultaneous filing for both indications; however, if the FDA requests additional data, the company has a fourth Phase 3 MDD study currently enrolling that can be completed if needed, while still proceeding with the GAD filing based on existing adequate data.
• DT402 (ASD Program): Following a positive "Early Signals of Efficacy" (ESOE) study, development for Autism Spectrum Disorder (ASD) is advancing; the company intends to publish study design concepts publicly soon.
• Pipeline Expansion: The company announced it will initiate a Phase 3 trial for PTSD in the coming year.
• Long-term Goals: Aiming to submit DT120 as a specific "classic psychedelic" with a label reflecting an "as-needed" or minimal necessary dosing paradigm, distinguishing it from chronic maintenance drugs.

Business Segments and Product Lines:

• DT120 (LSD): A pharmaceutically optimized LSD formulation in Zytus oral dissolving tablet format.
  • Successfully completed three Phase 3 studies (two in GAD, one in MDD) with positive readouts earlier in the summer.
  • Running Part B studies (9-month open-label extension) to gather real-world safety and efficacy data, allowing for up to four additional doses.
• DT402 (R-MDMA): The R-enantiomer of MDMA designed as a daily drug for ASD.
  • Focuses on core symptoms (social awareness, emotional awareness, communication) rather than perception changes.
  • Selected for its distinct biological profile: it generates social engagement without the stimulant-like or toxic effects associated with the S-enantiomer.

Market and Competitive Landscape:

• Regulatory Environment: Management perceives a significant shift in FDA attitude compared to five years ago; the agency is now viewed as enthusiastic about regulating psychedelics safely and efficiently, driven by societal pressure (e.g., veteran mental health crisis) and a desire to modernize oversight rather than slow the field.
• Differentiation vs. Competitors: Management believes DT120 is distinct from competitors (Compass Pathways' Psilocybin, Usona's LSD), positioning it as a true "classic psychedelic" with specific 5-HT2B binding characteristics, warranting individual regulatory treatment rather than category-wide labeling.
• Competitive Benchmarks: While investors may look to COMP360 (Compass) and Usona for REMS and labeling precedents, Definium argues its intentional study design and specific data points allow it to make superior arguments regarding REMS requirements (e.g., observation times) and redosing protocols.

Risks and Challenges:

• FDA Capacity: Acknowledged that the FDA is understaffed and facing political scrutiny, which could impact timelines, though the agency remains cooperative.
• Redosing Strategy: High risk of the drug not receiving approval for prophylactic use; the label is expected to restrict usage to treating active symptoms, limiting potential volume compared to daily maintenance drugs.
• ASD Safety Concerns: Potential safety risks regarding cardiac toxicity (valvulopathy) associated with MDMA derivatives, though management believes the R-enantiomer significantly mitigates these risks compared to racemic MDMA.
• Study Complexity: Managing "confounding" in study designs (adding 50mcg arms to mask treatment allocation) to ensure rigorous efficacy data.

Management Commentary and Tone:

• Tone: Highly confident, scientifically precise, and optimistic. Management expresses strong belief in the data quality and the safety of the regulatory pathway.
• Relationship with FDA: Highlights a strategic, respectful, and collaborative approach, noting that the company has influenced the current regulatory guidance for psychedelics and maintains open communication without pressuring the agency prematurely.
• Confidence: Management stated they have "the data in the bag" for DT120 and view the ongoing extension studies as supplementary rather than essential for the core efficacy claim.

Analyst Questions and Answers:

• Q: Single vs. Two Indication Filing: Management confirmed that while a simultaneous GAD/MDD filing is the goal, they are prepared to file GAD alone if FDA requires more MDD data, citing the existing MDD study as adequate for submission.
• Q: Study Design Nuance: Explained the inclusion of a lower dose (50mcg) control arm in half the studies to "confound" patients regarding their allocation, thereby strengthening the validity of the placebo effect measurement.
• Q: REMS and Labeling Expectations: Predicted that the DT120 label will reflect a non-prophylactic, as-needed redosing model, contrasting with the chronic dosing of current psychiatry drugs.
• Q: ASD Target Population: Clarified that early ASD studies focus on patients with preserved language skills to ensure accurate reporting of internal states, with plans to eventually include patients with more profound deficits.
• Q: Safety of R-MDMA: Addressed concerns about serotonin syndrome and cardiac toxicity, noting that the R-enantiomer lacks the stimulant effects and toxicity profile of the S-enantiomer, with extensive toxicology studies underway.

Other Key Points:

• Enantiomer Specificity: Emphasized the "nerdy" but critical scientific distinction between MDMA enantiomers; R-MDMA provides social benefits without the toxicity of the racemic drug.
• Data Availability: The FDA utilizes modern analytical tools and receives structured data files directly, allowing them to perform independent analyses of the study data.
• Real-World Evidence: The open-label extension phases (Part B) are crucial for generating data on the "naturalistic" treatment patterns and the long-term utility of the drug in clinical practice.